Board Member at Seattle Genetics, Inc.
Daniel Welch has served as a member of our board of directors since November 2015. Mr. Welch has been an Executive Partner at Sofinnova Ventures since 2015. From 2003 until October 2014, Mr. Welch was the Chairman, Chief Executive Officer and President of InterMune, Inc., which was listed on the Nasdaq Stock Market until the acquisition of the company by Roche. During his tenure, InterMune secured registration of Esbriet, the first medicine approved for idiopathic pulmonary fibrosis in Europe and the United States. Mr. Welch built the InterMune development and commercial teams that delivered the successful approval and launches of Esbriet in ...
Source: Intercept Pharmaceuticals, Inc. on 04/05/2017
By accessing Equilar Atlas, you can view bios, network, salary and wealth events of industry-leading executives like Daniel G. Welch. More specifically, you'll be able to:
Search for over 360,000 executive profiles.
Example: Daniel G. Welch
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.
Thank you for your interest.